Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | LTK | P29376 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | PRKX | P51817 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.56 |
| ▸ | MST1R | Q04912 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134888 | 1.00 | CSF1R (0.56) | CSF1RBTKPLK4CHEK1AURKA | |
| SCHEMBL31409300 | 0.85 | METAP2 (0.55) | CSF1RBTKPLK4CHEK1AURKA | |
| SCHEMBL30285533 | 0.84 | NOS1 (0.52) | NOS1AXLIDO1METAP2KIT | |
| SCHEMBL260364 | 0.84 | NOS1 (0.52) | NOS1AXLIDO1METAP2KIT | |
| Hydrochloric Acid SCHEMBL1056437 | 0.82 | NOS1 (0.50) | NOS1AXLIDO1METAP2KIT | |
| SCHEMBL7379757 | 0.82 | NOS1 (0.50) | NOS1AXLIDO1METAP2KIT | |
| SCHEMBL1743327 | 0.82 | CTNNB1 (0.49) | CSF1RBTKPLK4CHEK1AURKA | |
| SCHEMBL459667 | 0.81 | METTL3 (0.52) | KITNPC1LMNACYP1A2CYP3A4 | |
| SCHEMBL29702928 | 0.81 | NOS1 (0.53) | NOS1AXLIDO1METAP2KIT | |
| SCHEMBL6531813 | 0.80 | NOS1 (0.53) | CSF1RBTKPLK4CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4639437-A1 | SYSTEMS AND METHODS FOR PEST PRESSURE HEAT MAPS THAT CONVEY INFORMATION RELATING TO GENETIC MARKERS OF RESISTANCE TO PEST CONTROL PRODUCTS | FMC Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4496475-A2 | PROCESSES FOR CRYSTALLIZATION OF AMORPHOUS PESTICIDES AND FORMULATIONS THEREOF | FMC Corporation (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024137332-A1 | SYSTEMS AND METHODS FOR PEST PRESSURE HEAT MAPS THAT CONVEY INFORMATION RELATING TO GENETIC MARKERS OF RESISTANCE TO PEST CONTROL PRODUCTS | FMC CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230383292-A1 | TARGETING XIST AND RNA METHYLATION FOR X REACTIVATION THERAPY | THE GENERAL HOSPITAL CORPORATION | 2023-11-30 | — | — | US | disclosed |
| WO-2023183353-A2 | PROCESSES FOR CRYSTALLIZATION OF AMORPHOUS PESTICIDES AND FORMULATIONS THEREOF | FMC CORPORATION (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| CN-113999211-B | Indazole skeleton derivative containing 1,2,3-triazole with specific activity of resisting prostate cancer | 郑州大学 | 2022-11-29 | — | — | CN | disclosed |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-11-29 | — | — | US | disclosed |
| CN-110885328-B | Sulfonamide compounds as sodium channel blockers and uses thereof | 成都康弘药业集团股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022017836-A1 | FUNGICIDAL COMPOSITIONS COMPRISING (R)-2-[4-(4-CHLOROPHENOXY)-2-(TRIFLUOROMETHYL)PHENYL]-1- (1,2,4-TRIAZOL-1-YL)PROPAN-2-OL | BASF Agro B.V. (NL) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | CSF1R 2614/4885BTK 2457/4885PLK4 3124/4885 |
| US-12274697-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | CSF1R 4135/4885BTK 2009/4885PLK4 1797/4885 |
| US-20230383292-A1 | TARGETING XIST AND RNA METHYLATION FOR X REACTIVATION THERAPY | METTL16, NSUN2, METTL3 | CSF1R 3258/4885BTK 1014/4885PLK4 3677/4885 |
| US-11510920-B2 | Compositions and methods for treating EZH2-mediated cancer | EZH2, EZH1, EED | CSF1R 4135/4885BTK 2009/4885PLK4 1797/4885 |
| US-20230114294-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | EZH2, EZH1, EED | CSF1R 4135/4885BTK 2009/4885PLK4 1797/4885 |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, METTL16, DIMT1 | CSF1R 2614/4885BTK 2457/4885PLK4 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.